Arkolith/Insider Trading/ITCI/Form 4

Mates Sharon

Chairman and CEO, DirectorIntra-Cellular Therapies, Inc. (ITCI) · full profile →Form 4 · filed Apr 2, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
15
2 non-derivative · 13 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 2, 2025Disposed to issuer(D)190K$132.00$25.1M0
Apr 2, 2025Disposed to issuer(D)945K$132.00$124.8M0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 2, 2025Grant(A)35K—$035K
Apr 2, 2025Disposed to issuer(D)41K——0
Apr 2, 2025Grant(A)41K—$041K
Apr 2, 2025Disposed to issuer(D)121K——0
Apr 2, 2025Disposed to issuer(D)86K——0
Apr 2, 2025Disposed to issuer(D)41K——0
Apr 2, 2025Disposed to issuer(D)50K——0
Apr 2, 2025Disposed to issuer(D)53K——0
Apr 2, 2025Disposed to issuer(D)67K——0
Apr 2, 2025Disposed to issuer(D)138K——0
Apr 2, 2025Disposed to issuer(D)135K——0
Apr 2, 2025Disposed to issuer(D)35K——0
Apr 2, 2025Disposed to issuer(D)70K——0

Transaction Codes

D
Disposition to the issuer
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-049595) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML